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Introduction: Genome-wide association studies (GWAS) have con-
sistently identiﬁed speciﬁc lung cancer susceptibility regions. We 
evaluated the lung cancer–predictive performance of single-nucleo-
tide polymorphisms (SNPs) in these regions.
Methods: Lung cancer cases (N = 778) and controls (N = 1166) were 
genotyped for 77 SNPs located in GWAS-identiﬁed lung cancer sus-
ceptibility regions. Variable selection and model development used 
stepwise logistic regression and decision-tree analyses. In a subset 
nested in the Pittsburgh Lung Screening Study, change in area under 
the receiver operator characteristic curve and net reclassiﬁcation 
improvement were used to compare predictions made by risk factor 
models with and without genetic variables.
Results: Variable selection and model development kept two SNPs in 
each of three GWAS regions, rs2736100 and rs7727912 in 5p15.33, 
rs805297 and rs1802127 in 6p21.33, and rs8034191 and rs12440014 
in 15q25.1. The ratio of cases to controls was three times higher among 
subjects with a high-risk genotype in every one as opposed to none of 
the three GWAS regions (odds ratio, 3.14; 95% conﬁdence interval, 
2.02–4.88; adjusted for sex, age, and pack-years). Adding a three-level 
classiﬁed count of GWAS regions with high-risk genotypes to an age 
and smoking risk factor-only model improved lung cancer predic-
tion by a small amount: area under the receiver operator characteris-
tic curve, 0.725 versus 0.717 (p = 0.056); overall net reclassiﬁcation 
improvement was 0.052 across low-, intermediate-, and high- 6-year 
lung cancer risk categories (<3.0%, 3.0%–4.9%, ≥5.0%).
Conclusion: Specifying genotypes for SNPs in three GWAS-
identiﬁed susceptibility regions improved lung cancer prediction, but 
probably by an extent too small to affect disease control practice.
Key Words: Lung cancer, Single-nucleotide polymorphism, Risk 
prediction.
(J Thorac Oncol. 2015;10: 1538–1545)
Typically using many hundreds of thousands of single-nucleotide polymorphisms (SNPs) and working to identify 
regions of the human genome that associate with a particular 
trait or disease, genome-wide association studies (GWAS) 
compare the frequency of common inherited variation between 
two groups of individuals. Comparing individuals with and 
without lung cancer, this approach has reproducibly identi-
ﬁed several susceptibility regions of interest.1–5 Although 
these genomic regions contain multiple potentially relevant 
genes, we currently lack a ﬁrm biological understanding of the 
causal molecular processes that link them to lung cancer.6 The 
regions implicated in GWAS of lung cancer may act indirectly 
by affecting intensity of cigarette smoking or personal sus-
ceptibility to chronic obstructive pulmonary disease (COPD),7 
two potent lung cancer risk factors.8
The identiﬁcation of susceptibility loci has stimulated 
interest in the use of genetic information to help identify 
persons at particularly high risk of developing lung cancer.9 
Genetic information might be used to improve the predic-
tion accuracy of currently available models based on cigarette 
smoking and age.10–15 Selecting persons according to predic-
tions made by more accurate models may help improve the 
efﬁciency and safety of lung cancer screening with low-dose 
computed tomography (CT),16 a public health-relevant issue in 
light of the recent Centers for Medicare and Medicaid Services 
funding decision adding lung cancer screening to Medicare.17 
With these thoughts in mind, we aimed to evaluate the predic-
tive performance of common SNPs located in regions previ-
ously identiﬁed in GWAS of lung cancer or COPD.1–5,18–27
MATERIALS AND METHODS
Study Subjects
Consented subjects originated from two studies approved 
by the University of Pittsburgh Institutional Review Board. 
A clinical study contributed 45- to 85-year-old 10 or more 
pack-year current or former cigarette smokers who received 
diagnostic, staging, or therapeutic surgery after 2001 at the 
University of Pittsburgh Medical Center for noncarcinoid 
lung cancer and who provided a research blood sample within 
1 year of diagnosis. The second group of subjects came from 
the Pittsburgh Lung Screening Study (PLuSS), a Pittsburgh-
based CT lung cancer screening study that enrolled, between 
2002 and 2005, 50- to 79-year-old current or former cigarette 
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smokers (≥ half pack per day for ≥25 years, quit ≤10 years).28 
This second study group included a set of lung cancer cases, 
and a lung cancer-free simple random sample, enriched with 
persons found to have one or more benign noncalciﬁed nod-
ules, 5 to 19 mm in diameter on ﬁrst CT, or growing or new 
on follow-up CT. Our genotyping studies added persons with 
nodules to enhance parallel studies of circulating protein-
based biomarkers and early lung cancer detection.
These two sources identiﬁed 2292 individuals in all, 
including 2189 (95.5% of 2292) with DNA available for anal-
ysis and 2117 (96.7% of 2189) with a DNA sample that passed 
all genotype quality control checks, including SNP call rate 
95% or greater. After 173 exclusions (ﬁve for missing sex, one 
for age <50 years, 10 for <10 pack-years, 14 for lung cancer 
not biopsy conﬁrmed, and 143 for non-white race), 1944 sub-
jects (91.8% of 2117) remained, 778 lung cancer cases (600 
clinical and 178 PLuSS), and 1166 lung cancer-free controls 
(861 selected at random and 305 chosen intentionally for nod-
ule presence). Active lung cancer surveillance after an initial 
CT screening extended a median 7.3 years (5th to 95th percen-
tile 1.2 to 10.8 years) and a median 10.4 years (5th to 95th per-
centile 8.8 to 11.7 years) for control subjects who were dead 
and alive, respectively, at last contact. To reduce confounding 
related to population stratiﬁcation, analyses excluded non-
white race subjects and used ancestry-informative markers to 
verify white race.
For clinical cases, ancillary data (sex, age at diagnosis, 
cigarette pack-years, and spirometry results) were extracted 
from medical records. For PLuSS cases and controls, ancillary 
data collected through standardized self-administered question-
naire included smoking intensity (cigarettes per day), years of 
smoking, family history of lung cancer, respiratory symptoms 
(cough, phlegm, and wheeze), and medical history (doctor diag-
nosis of emphysema or bronchitis). As previously described,29 
additional baseline information available for the PLuSS cases 
and controls included severity of airflow limitation measured by 
spirometry and severity of emphysema seen on CT.
SNP Selection and Genotyping
An Illumina Custom GoldenGate 384 SNP Panel was 
used to genotype the 778 lung cancer cases and 1166 controls. 
The panel included in total 77 SNPs (listed in Supplemental 
Table 1, Supplemental Digital Content, http://links.lww.com/
JTO/A889) located in chromosomal regions identiﬁed by 
GWAS for association with lung cancer risk or COPD. Two 
SNPs failed (genotype called in <95% of samples) and a third 
violated Hardy-Weinberg equilibrium (p < 0.001). Subsequent 
analyses restricted to the remaining 74 SNPs identiﬁed that in 
our study population 18 SNPs were associated with lung cancer 
risk at p
trend
 < 0.1 (Table 1). Efforts to develop parsimonious 
models started with these 18 SNPs, two, six, and 10 in chromo-
somal regions 5p15.33, 6p21.3, and 15q25.1, respectively.
Statistical Analysis
Using a data set that replaced missing genotypes with val-
ues imputed from haplotype frequencies estimated by expecta-
tion maximization,30 we used stepwise logistic regression (p
entry
 
< 0.25, p
stay
 < 0.15), one GWAS region at a time, to select SNPs 
independently associated with lung cancer risk. Using weights 
to balance the numbers of cases and controls and working one 
GWAS region at a time, we used a WEKA31 implementation 
TABLE 1. SNPs Associated with Lung Cancer Risk at ptrend < 0.1
a
rs Number Chromosome Positionb Gene Region Casesc Controlsc OR 95% CI p
trend
rs2736100 5 1286401 TERT 5p15.33 224/396/158 292/618/256 0.89 0.78–1.02 0.091
rs7727912 5 1318845 CLPTM1L 5p15.33 611/155/10 967/193/6 1.32 1.07–1.64 0.010
rs805297 6 31654829 APOM, BAG6 6p21.33 360/324/84 467/482/161 0.84 0.73–0.96 0.010
rs2295663 6 31701518 ABHD16A,MIR4646 6p21.33 672/101/5 1043/119/4 1.33 1.02–1.73 0.033
rs805293 6 31720741 LY6G6C 6p21.33 225/391/162 296/579/291 0.86 0.75–0.98 0.019
rs805304 6 31730311 CLIC1, DDAH2 6p21.33 306/371/101 520/511/134 1.16 1.01–1.33 0.030
rs707939 6 31758911 MSH5 6p21.33 320/358/99 439/534/193 0.86 0.75–0.98 0.023
rs1802127 6 31762148 MSH5 6p21.33 732/46/0 1119/46/1 1.45 0.96–2.19 0.075
rs13180 15 78497146 IREB2 15q25.1 332/357/89 446/545/175 0.84 0.74–0.96 0.012
rs4362358 15 78503762 IREB2||HYKK 15q25.1 335/354/89 450/542/174 0.84 0.74–0.96 0.012
rs8034191 15 78513681 HYKK 15q25.1 270/374/134 469/546/151 1.23 1.08–1.40 0.002
rs4461039 15 78525105 HYKK 15q25.1 523/230/25 710/403/53 0.78 0.67–0.92 0.004
rs16969968 15 78590583 CHRNA5 15q25.1 276/378/124 471/545/149 1.19 1.04–1.36 0.010
rs12914385 15 78606381 CHRNA3 15q25.1 229/390/159 409/570/186 1.23 1.08–1.41 0.002
rs12443170 15 78615394 CHRNA3 15q25.1 641/126/11 877/265/18 0.71 0.58–0.87 0.001
rs8042374 15 78615690 CHRNA3 15q25.1 521/231/26 697/413/55 0.77 0.65–0.90 0.001
rs12440014 15 78634384 CHRNB4 15q25.1 519/232/27 682/414/69 0.73 0.62–0.85 0.000
rs1316971 15 78638168 CHRNB4 15q25.1 546/210/22 744/377/45 0.78 0.66–0.92 0.004
aOR, 95% CI, and p
trend
 results from logistic regression analysis.
bBased on dbSNP Human Build 142 (GRCh38).
cCase and control counts: common allele homozygote/heterozygote/minor allele homozygote.
OR, odds ratio per minor allele; CI, conﬁdence interval; SNP, single-nucleotide polymorphism.
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of the C4.5 algorithm32 to translate the independent SNP vari-
ables into decision trees. To evaluate the effects of genetic vari-
ables on lung cancer risk prediction, we restricted analyses to 
the lung cancer cases nested in PLuSS, along with the com-
parable controls selected at random. We used net reclassiﬁca-
tion improvement (NRI33) to compare lung cancer predictions 
made by appropriately calibrated models with and without 
genetic variables. Base models estimated individual risks by 
means of logistic regression and a risk factor score that tallied 
points for the following four risk factors: duration of smoking, 
age, cigarettes per day, and smoking status (Supplemental Table 
2, Supplemental Digital Content, http://links.lww.com/JTO/
A889). To recalibrate a prediction model, we reweighted case 
and control observations as desired and then re-estimated the 
intercept term in logistic regression with the logit of case-con-
trol model predictions entered as an offset. Statistical analyses 
were completed in SAS 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Selected characteristics of the study population are pre-
sented in Table 2. Women were similarly represented in the 
case and control groups. The cases were signiﬁcantly older 
than the controls and had accrued more cigarette pack-years. 
The majority of the cases were diagnosed with non–small-cell 
lung cancer; adenocarcinoma and squamous-cell carcinoma 
were the most often observed histological types.
Stepwise logistic regression selected two, three, and 
two SNPs in 5p15.33 (rs2736100 and rs7727912), 6p21.33 
(rs805297, rs2295663, and rs1802127), and 15q25.1 
(rs8034191 and rs12440014), respectively (Table 3). The 
5p15.33 decision-tree analysis produced a lung cancer class 
that included both the carriers of the rs7727912 minor allele 
and the homozygotes for the rs2736100 common allele 
(Supplemental Figure 1A, Supplemental Digital Content, 
http://links.lww.com/JTO/A889). The 6p21.33 lung can-
cer class included both the carriers of the rs1802127 minor 
allele and the homozygotes for the rs805297 common allele 
(Supplemental Figure 1B, Supplemental Digital Content, 
http://links.lww.com/JTO/A889). Finally, the 15q25.1 lung 
cancer class included rs12440014 common allele homozy-
gotes with one or two copies of the rs8034191 minor allele 
(Supplemental Figure 1C, Supplemental Digital Content, 
http://links.lww.com/JTO/A889). All subsequent results used 
these classiﬁcation results from decision-tree analysis to dis-
tinguish high from low risk for lung cancer.
Control group characteristics according to decision-
tree–determined risk at 5p15.33, 6p21.33, and 15q25.1 are 
presented in Supplemental Tables 3, 4, and 5 (Supplemental 
Digital Content, http://links.lww.com/JTO/A889), respec-
tively. High-risk controls had more emphysema on CT 
(p = 0.22, <0.01, and <0.01 for 5p15.33, 6p21.33, and 15q25.1, 
respectively). Twenty-one percent, 43%, and 36% of controls 
satisﬁed decision-tree deﬁnitions of high risk at zero, only 
one, and more than one GWAS region, respectively. Cigarettes 
per day, pack-years, prevalence of doctor-diagnosed emphy-
sema or bronchitis, and emphysema severity increased along 
with the number of GWAS regions that satisﬁed decision-tree 
deﬁnitions of high risk (Table 4).
TABLE 2. Selected Characteristics of the Study Population 
Stratified by Case-Control Status
Cases Controls
paN % N %
N 778 100.0 1166 100.0
Sex 0.85
  Male 405 52.1 602 51.6
  Female 373 47.9 564 48.4
Age, yrb <0.0001
  45–59 142 18.3 665 57.0
  60–69 295 37.9 392 33.6
  ≥80 341 43.8 109 9.3
Pack-years <0.01
  <35 183 23.5 292 25.0
  35–49 166 21.3 300 25.7
  50–64 186 23.9 298 25.6
  ≥65 243 31.2 276 23.7
GOLDc <0.0001
  No limitation 236 34.2 652 55.9
  Mild 125 18.1 165 14.2
  Moderate 238 34.5 265 22.7
  Severe 91 13.2 84 7.2
Histology
  Adenocarcinoma 350 45.0
  Squamous cell 271 34.8
  Adenosquamous 29 3.7
  Large cell 39 5.0
  Non–small-cell cancer 46 5.9
  Small-cell cancer 43 5.5
aDifferences in characteristics between cases and controls were assessed using chi-
square tests.
bAge at diagnosis and age at PLuSS enrollment for cases and controls, respectively.
cEighty-eight cases were missing spirometry data that predated lung cancer 
diagnosis.
GOLD, Global Initiative for Chronic Obstructive Lung Disease severity of airflow 
limitation;43 PluSS, Pittsburgh Lung Screening Study.
TABLE 3. SNPs Identified by Stepwise Logistic Regression, 
by GWAS Region
rs Number OR 95% CI p
trend
5p15.33 AUC 0.537
rs2736100 0.90 0.79–1.03 0.13
rs7727912 1.32 1.06–1.63 0.01
6p21.33 AUC 0.540
rs805297 0.86 0.75–0.98 0.03
rs2295663 1.28 0.98–1.67 0.07
rs1802127 1.41 0.93–2.13 0.11
15q25.1 AUC 0.557
rs8034191 1.13 0.98–1.31 0.08
rs12440014 0.77 0.65–0.91 <0.01
AUC, area under receiver operator characteristic curve; GWAS, genome-wide 
association studies; OR, odds ratio; SNP, single-nucleotide polymorphism; CI, 
conﬁdence interval.
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TABLE 4. Characteristics of Controls (N = 1113) According to the Number of High-Risk GWAS Regionsa
0 1 >1
pbN % N % N %
N 231 100.0 478 100.0 404 100.0
Year 0.36
  2002 73 31.6 127 26.6 115 28.5
  2003 89 38.5 219 45.8 184 45.5
  2004–2005 69 29.9 132 27.6 105 26.0
Sex 0.22
  Male 127 55.0 254 53.1 196 48.5
  Female 104 45.0 224 46.9 208 51.5
Age, yr 0.87
  50–59 131 56.7 284 59.4 227 56.2
  60–69 79 34.2 151 31.6 136 33.7
  70–79 21 9.1 43 9.0 41 10.1
Family historyc 1.00
  No 192 83.8 398 84.0 337 83.8
  Yes 37 16.2 76 16.0 65 16.2
Symptoms, N 0.07
  0 68 29.4 165 34.5 137 33.9
  1 67 29.0 148 31.0 104 25.7
  2 67 29.0 103 21.5 91 22.5
  3 29 12.6 62 13.0 72 17.8
Duration of smoking, yr 0.73
  <30 10 4.3 34 7.1 30 7.4
  30–39 109 47.2 221 46.2 177 43.8
  40–49 83 35.9 172 36.0 147 36.4
  ≥50 29 12.6 51 10.7 50 12.4
Cigarettes/day 0.005
  <20 89 38.5 131 27.4 100 24.8
  20–29 88 38.1 214 44.8 168 41.6
  30–39 34 14.7 85 17.8 80 19.8
  ≥40 20 8.7 48 10.0 56 13.9
Pack-years 0.020
  <35 76 32.9 115 24.1 87 21.5
  35–49 52 22.5 134 28.0 101 25.0
  50–64 56 24.2 125 26.2 103 25.5
  ≥65 47 20.3 104 21.8 113 28.0
COPD 0.005
  No 194 84.0 391 81.8 301 74.5
  Yes 37 16.0 87 18.2 103 25.5
Emphysema <0.0001
  None 137 59.3 280 58.6 199 49.3
  Trace 53 22.9 96 20.1 68 16.8
  Mild 29 12.6 57 11.9 72 17.8
  Moderate-severe 12 5.2 45 9.4 65 16.1
GOLD 0.059
  No limitation 140 60.6 267 55.9 214 53.0
  Mild 36 15.6 72 15.1 48 11.9
  Moderate 40 17.3 110 23.0 103 25.5
  Severe 15 6.5 29 6.1 39 9.7
aFifty-three subjects could not be classiﬁed because of missing genotype data.
bDifferences in characteristics between groups were assessed using chi-square tests.
cFirst-degree relative with lung cancer (data missing in two, four, and two controls with 0, 1, and >1 GWAS risk marker).
GWAS, genome-wide association studies; symptoms, symptom (cough, phlegm, and wheeze) count; COPD, chronic obstructive pulmonary disease (doctor diagnosis of emphysema 
or bronchitis); GOLD, Global Initiative for Chronic Obstructive Lung Disease severity of airflow limitation.43
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We tabulated cases and controls, ﬁrst according to a 
three GWAS region cross-classiﬁcation of decision-tree–
determined SNP conﬁgurations associated with high versus 
low lung cancer risk and then according to a three-level classi-
ﬁed count of GWAS regions showing the high-risk SNP con-
ﬁguration (Table 5). Table 5 shows, for example, a threefold 
higher ratio of cases to controls among subjects with a high-
risk genotype in every one as opposed to none of the three 
GWAS regions (odds ratio, 3.14; 95% conﬁdence interval, 
2.02–4.88; adjusted for sex, age, and cigarette pack-years). 
Unadjusted and adjusted (sex, age, and pack-years) lung 
cancer risk increased (p < 0.001) in step with the number of 
GWAS regions that contained a SNP conﬁguration associated 
with high lung cancer risk.
We subsequently used the prospective data from 
PLuSS to make externally valid inferences about the 
contributions from genetic variables to risk prediction. 
Associations between the GWAS variables and lung cancer 
were preserved, even after adjustments for a score that added 
points together for the four risk factors: duration of smok-
ing, age, cigarettes per day, and smoking status (Table 5; 
Supplemental Table 2, Supplemental Digital Content, http://
links.lww.com/JTO/A889). Adding a three-level high-risk 
GWAS region count variable (0, 1, and ≥2 high-risk GWAS 
regions) to the risk factor score-only model increased area 
under the receiver operator characteristic curve by 0.008 
units (0.717 to 0.725; p = 0.056). We recalibrated both the 
risk factor score-only model and the risk factor score plus 
GWAS region count variable model to four events per 100 
(absolute 6-year lung cancer incidence observed in PLuSS; 
data not shown). Across low- (<3.0%), intermediate- (3.0%–
4.9%), and high- (≥5.0%) 6-year risk categories, adding the 
GWAS region count variable improved net reclassiﬁcation 
among cases by 7.7% (100 [(3.6 + 0.7 + 0.0) – (0.7 + 0.5 + 
0.0)] / 40.0) and worsened net reclassiﬁcation among non-
cases by 2.6% (100 [(21.2 + 28.1 + 0.0) – (51.8 + 22.4 + 
0.0)] / 960.0; overall NRI = 0.077–0.026 = 0.052; Table 6).
DISCUSSION
Having genotyped 778 cases and 1166 controls for 77 
SNPs located in regions identiﬁed by GWAS of lung cancer or 
COPD, our methods built on six SNPs, two from each of the 
following three regions, 5p15.33, 6p21.33, and 15q25.1. These 
three regions have withstood the test of time as the source of 
valid markers of susceptibility to lung cancer in white popula-
tions7 and contain cancer-relevant genes that include telom-
erase reverse transcriptase (TERT; essential for telomerase 
production and maintenance of telomeres) and CLPTM1-
like (CLPTM1L; reported to protect against apoptosis34) in 
5p15.33, BCL2-associated athanogene 6 (BAG6; required 
for p53-mediated response to DNA damage and stress) and 
mutS homolog 5 (MSH5; involved in DNA mismatch repair) 
TABLE 5. Lung Cancer Cases and Controls, Classified According to SNP Configuration in Three GWAS Regions
GWAS Regions  
Cross-Classified All Cases (N = 766) and All Controls (N = 1113)a
PLuSS Case (N = 168) and Random Control Subsets  
(N = 816)b
15q25.1 6p21.33 5p15.33 Case Control OR 95% CI OR
a
95% CI Case Control OR 95% CI OR
b
95% CI
LO LO LO 109 231 Ref. Ref. 22 168 Ref. Ref.
LO LO HI 86 118 1.54 1.08–2.21 1.57 1.04–2.36 23 86 2.04 1.08–3.87 1.90 0.98–3.71
LO HI LO 108 185 1.24 0.89–1.72 1.19 0.82–1.73 23 143 1.23 0.66–2.30 1.16 0.60–2.22
LO HI HI 80 122 1.39 0.97–2.00 1.33 0.88–2.01 21 87 1.84 0.96–3.54 1.56 0.79–3.07
HI LO LO 115 175 1.39 1.00–1.93 1.66 1.14–2.40 23 126 1.39 0.74–2.61 1.36 0.71–2.60
HI LO HI 83 100 1.76 1.22–2.55 1.84 1.21–2.80 19 71 2.04 1.04–4.01 1.95 0.97–3.95
HI HI LO 100 112 1.89 1.33–2.69 2.07 1.38–3.09 20 80 1.91 0.99–3.70 1.76 0.88–3.52
HI HI HI 85 70 2.57 1.74–3.80 3.14 2.02–4.88 17 55 2.36 1.17–4.76 2.48 1.19–5.18
Countc
All Cases (N = 766) and All Controls (N = 1113)a PLuSS Case (N = 168) and Random Control Subsets (N = 816)b
Case Control OR 95% CI OR
a
95% CI Case Control OR 95% CI OR
b
95% CI
0 109 231 Ref. Ref. 22 168 Ref. Ref.
1 309 478 1.37 1.05–1.79 1.45 1.07–1.96 69 355 1.48 0.89–2.48 1.41 0.83–2.41
2 263 334 1.67 1.26–2.21 1.72 1.25–2.36 60 238 1.93 1.14–3.26 1.74 1.01–3.01
3 85 70 2.57 1.74–3.80 3.14 2.02–4.88 17 55 2.36 1.17–4.76 2.48 1.19–5.18
0 109 231 Ref. Ref. 22 168 Ref. Ref.
1 309 478 1.37 1.05–1.79 1.44 1.07–1.96 69 355 1.48 0.89–2.48 1.41 0.83–2.41
≥2 348 404 1.83 1.40–2.39 1.94 1.43–2.64 77 293 2.01 1.21–3.34 1.86 1.10–3.17
aTwelve cases and 53 controls could not be classiﬁed because of missing genotype data.
bTen cases and 45 controls could not be classiﬁed because of missing genotype data.
cCount of GWAS regions with SNP conﬁgurations associated with high lung cancer risk.
GWAS, genome-wide association studies; SNP, single-nucleotide polymorphism; CI, conﬁdence interval; PluSS, Pittsburgh Lung Screening Study; LO, decision-tree–
determined SNP conﬁguration associated with low lung cancer risk; HI, decision-tree–determined SNP conﬁguration associated with high lung cancer risk; OR, odds ratio; 
OR
a
, odds ratio adjusted of sex, age (three groups), and pack-years (four groups); OR
b
, odds ratio adjusted for a risk factor score that tallied points for duration of smoking, age, 
cigarettes per day, and smoking status (Supplemental Table 2, Supplemental Digital Content, http://links.lww.com/JTO/A889).
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in 6p21.33, and the nicotinic cholinergic receptor genes 
(CHRNA3, CHRNA4, CHRNA5; associated with nicotine 
addiction and smoking cessation) in 15q25.1. Using ancil-
lary information provided by the lung cancer-free controls, 
our results shown in Table 4 support associations previously 
reported between GWAS-identiﬁed markers of lung cancer 
risk and other factors capable of mediating the lung cancer 
effects of these inherited genetic differences. Mediating factors 
relevant to our study included intensity of cigarette smoking, 
as measured by cigarettes per day, and COPD, as measured by 
self-reported doctor diagnosis, emphysema on CT, and airflow 
limitation on spirometry. Each GWAS region appeared to con-
tribute independently to risk, a pattern discernable by compar-
ing subjects with high-risk genotypes in only one as opposed 
to none of the three GWAS regions (odds ratio [95% conﬁ-
dence interval] for high GWAS risk at 5p15.33 only, 6p21.33 
only, and 15q25.1 only, respectively, 1.54 [1.08–2.21], 1.24 
[0.89–1.72], and 1.39 [1.00–1.93]; Table 5). Statistical control 
for case-control differences in age and smoking did not dimin-
ish these lung cancer associations with genetic risk (Table 5).
By comparing extreme categories, a high-risk genotype 
in every one as opposed to none of the three GWAS regions, 
we explored the maximum extent to which GWAS SNP clas-
siﬁcations may discriminate between persons with and with-
out lung cancer risk. Six percent and 21% of 1113 controls 
had high-risk genotypes in three and zero GWAS regions, 
respectively, with the ratio of cases to controls signiﬁcantly 
elevated threefold in the former as opposed to the latter cat-
egory after adjustment for sex, age, and cigarette pack-years. 
However, to illustrate the potential usefulness of the lung 
cancer discrimination achievable with GWAS SNP classiﬁca-
tion in practice, we formed three prudent categories deﬁned 
by presence of a high-risk genotype in none, only one, and 
more than one GWAS region. Adding this high-risk GWAS 
region count variable to an age and smoking risk factor-only 
model improved lung cancer prediction, as measured by an 
area under the receiver operator characteristic curve change 
of 0.008 and an NRI
overall
 of 0.052 across low-, intermediate-, 
and high-risk categories. These risk categories spanned the 
average 6-year lung cancer risk observed in PLuSS, a repre-
sentative cohort of current and former smokers.28 To discuss 
these improvements in possibly more meaningful terms, we 
will use our theoretical cohort of 1000 persons (Table 6) to 
describe reclassiﬁcation based on number of high-risk GWAS 
regions between low- and intermediate-risk categories, cat-
egories sensibly judged to deﬁne levels of lung cancer risk 
insufﬁcient and sufﬁcient for CT screening. Number of high-
risk GWAS regions reclassiﬁed 0.7 cases from low to interme-
diate risk and 0.5 cases from intermediate to low risk, changes 
associated with a 0.5 percentage-point improvement in the 
sensitivity of prediction (100 (0.7 – 0.5) / 40). It reclassiﬁed 
28.2 controls from intermediate to low risk and 22.4 controls 
from low to intermediate risk, changes associated with a 0.7 
percentage-point improvement in the speciﬁcity of prediction 
(100 (28.2 – 22.4) / 960). Even for persons with genuinely 
borderline-risk proﬁles, these improvements in sensitivity and 
speciﬁcity may not offset genotyping costs.
Using PLuSS, an illustrative cohort of current and 
former cigarette smokers,28 we evaluated SNPs in GWAS-
identiﬁed regions as predictors of lung cancer risk, an effort 
only possible with prospective data. Several previous stud-
ies have measured the improvements achieved by adding 
SNP genotype information to an otherwise conventional 
lung cancer prediction model.35–39 However, none used pro-
spective data to systematically evaluate SNPs from GWAS 
regions. Though unique in these regards, our study faced 
several limitations. First, the numbers of cases and controls 
available, particularly the number of cases nested in PLuSS, 
was relatively small, which limited the precision of some of 
our estimates of association between genetic risk and lung 
cancer (Table 5). Second, having used statistical criteria to 
select six SNPs from a list of 74 candidates, we did not cor-
rect our estimates of prediction accuracy for model overﬁt-
ting. Therefore, the improvements in prediction attributed to 
genetic variables are optimistic, potentially representing only 
an upper bound of the beneﬁts that might be possible. Third, 
not all cases and controls came from a single well-deﬁned 
source. To help select SNPs and build models, we supple-
mented the cases nested in PLuSS with cases seen in the 
clinic and added subjects with one or more benign nodules 
to the controls randomly selected from PLuSS. However, 
we did not observe statistically signiﬁcant differences in 
TABLE 6. Theoretical Cohort of 1000 Persons with 4% Average Lung Cancer Risk, Classified According to Lung Cancer 
Outcome and Lung Cancer Risk as Predicted by Risk Factor-Onlya and Risk Factor Plus GWAS Region Count Variable Models
Risk Factor Plus GWAS Prediction
Risk Factor-Only Prediction
Total≥0.05 ≥0.03 <0.05 <0.03
Lung cancer ≥0.05 20.2 3.6 0.0 23.8
≥0.03 <0.05 0.7 6.4 0.7 7.9
<0.03 0.0 0.5 7.9 8.3
Total 21.0 10.5 8.6 40.0
No lung cancer ≥0.05 198.8 51.8 0.0 250.6
≥0.03 <0.05 21.2 154.1 22.4 197.6
<0.03 0.0 28.2 483.5 511.8
Total 220.0 234.1 505.9 960.0
aPredictions based on a risk factor score that tallied points for duration of smoking, age, cigarettes per day, and smoking status (Supplemental Table 2, Supplemental Digital Content, 
http://links.lww.com/JTO/A889).
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genotype frequencies between cases obtained from the clinic 
as opposed to PLuSS or between controls selected randomly 
as opposed to intentionally (data not shown). Fourth, we 
based estimates of NRI on notions about current and for-
mer smokers who may or may not be appropriate candidates 
for lung cancer screening with low-dose CT. No univer-
sally accepted risk threshold exists for separating smokers 
between these two groups.9 However, when divided at the 
0.03 risk threshold by the risk factor-only model used for 
NRI calculation (Table 6), controls randomly selected from 
PLuSS split between a lower (N = 450) and higher (N = 411) 
risk group, two thirds in the former failing and nearly all 
(93%) in the latter satisfying minimum age and pack-year 
requirements for lung cancer screening, as established by 
the U.S. Preventive Services Task Force.40 Finally, our base 
models considered a limited set of risk factors related to sex, 
age, or smoking. Approaches that consider additional risk 
factors, such as COPD, may reduce even further the incre-
mental improvements in prediction possible through genetic 
information.
In conclusion, in line with what has been reported for 
other cancer sites,41,42 adding genetic information from six 
SNPs located in genomic regions identiﬁed by GWAS to basic 
models that included critical risk factors related to age and 
smoking resulted in only small improvements in lung cancer 
risk prediction. Unfortunately, the improvements observed are 
likely too small to affect disease control practice.
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